Merck & Co., Inc. Forecasted to Post Q4 2025 Earnings of $2.39 Per Share (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) – Analysts at Leerink Partnrs boosted their Q4 2025 EPS estimates for shares of Merck & Co., Inc. in a research note issued on Saturday, April 20th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnings per share of $2.39 for the quarter, up from their previous estimate of $2.37. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $8.59 per share.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The firm had revenue of $14.63 billion during the quarter, compared to analyst estimates of $14.49 billion. During the same quarter last year, the business earned $1.62 EPS. The company’s revenue was up 5.8% compared to the same quarter last year.

MRK has been the subject of several other research reports. Truist Financial reiterated a “buy” rating and issued a $142.00 price objective (up previously from $139.00) on shares of Merck & Co., Inc. in a research note on Thursday, March 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $135.00 price objective on shares of Merck & Co., Inc. in a research note on Thursday, April 18th. StockNews.com upgraded shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 2nd. Barclays lifted their price objective on shares of Merck & Co., Inc. from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. Finally, UBS Group lifted their price objective on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $131.25.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $127.01 on Tuesday. The company has a fifty day moving average of $126.26 and a 200-day moving average of $115.59. The firm has a market capitalization of $321.72 billion, a P/E ratio of 907.21, a P/E/G ratio of 1.64 and a beta of 0.38. The company has a quick ratio of 1.00, a current ratio of 1.25 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a twelve month low of $99.14 and a twelve month high of $133.10.

Hedge Funds Weigh In On Merck & Co., Inc.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vermillion & White Wealth Management Group LLC purchased a new position in Merck & Co., Inc. during the fourth quarter valued at $27,000. Bare Financial Services Inc purchased a new position in Merck & Co., Inc. during the fourth quarter valued at $28,000. Burkett Financial Services LLC purchased a new position in Merck & Co., Inc. during the fourth quarter valued at $28,000. Rakuten Securities Inc. purchased a new position in Merck & Co., Inc. during the fourth quarter valued at $30,000. Finally, RIA Advisory Group LLC purchased a new position in Merck & Co., Inc. during the fourth quarter valued at $30,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insider Activity at Merck & Co., Inc.

In other news, EVP Steven Mizell sold 50,694 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $126.65, for a total value of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares in the company, valued at $2,991,346.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Joseph Romanelli sold 1,000 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the completion of the sale, the insider now owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Steven Mizell sold 50,694 shares of the firm’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the completion of the sale, the executive vice president now directly owns 23,619 shares of the company’s stock, valued at approximately $2,991,346.35. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.